World leaders in
complex human diseases
Syreon is driven by senior researchers who link teams of expert clinical investigators, molecular scientists, data scientists and health economists across academia, industry and the healthcare sector.
Syreon works with an elite portfolio of Fortune 500 companies, top-20 pharma and emerging biotech corporations to identify therapeutic needs, to evaluate new drug treatments and companion diagnostics, to evaluate costs and develop pricing strategies, to support market access, and to monitor safe and effective clinical use and economic value in today's competitive health environment.
We excel in health sciences, digital informatics and computational medicine across all areas from Precision Medicine to Post-marketing Surveillance and Personalized Care.
Our head offices in North America and Europe coordinate an international network of expert research teams providing professional support to sponsors, investigators, providers, and payers. Our services cover all phases of study planning, operation and analysis to ensure safe, effective and value-driven clinical use of new drugs, diagnostics and medical devices.
For the past 25 years we have been at the leading edge of the rapid advances in new drugs, diagnostics and medical devices in North America, the European Union and many countries around the world.
Our scientists are at the forefront of personalized therapeutics in a broad range of areas, from genomics and companion diagnostics to therapeutic trials, cellular replacement and stem cell therapeutics, health quality measurement, disease burden estimation, economic modeling and policy analysis in preparation for the revolution in valuation and pricing.
Transforming care in
complex and chronic diseases
and accelerated approval:
Current treatment strategies will be replaced as molecular and genomic signatures of complex disease guide targeted biological therapies focusing on precise mechanisms.
and targeted benefit / value:
Reimbursement will be governed by detailed performance-based pricing to ensure safety and cost-efficiency of these exciting new therapies within tightly limited healthcare budgets.
and real-world evidence:
And these new drugs will be delivered closer to home for convenience and efficiency through outreach programs with expert systems and telemedicine support.
health sciences research
RESEARCH IN COMPLEX DISORDERS AND CHRONIC OR RARE DISEASES
Syreon excels in common therapeutic areas and in the advancing technologies of molecular sciences, stem cell therapeutics, immune disease and immuno-oncology, and in the broader areas of targeted therapy. We complement our trials with companion studies to evaluate costs and develop pricing strategies, to support market access, and to monitor effective clinical use and economic value in today's competitive health environment.
USING OUR GLOBAL SYSTEMS AND DIGITAL RESEARCH NETWORKS
Our digital networks link leading academic institutions, community sites, patients and care-givers, providers and payers in thousands of locations across more than 40 countries. Our studies can each engage more than 30,000 participants enabling the real-time investigation of new treatments; the evaluation of clinical, economic and health benefit; and the safe, effective and cost-efficient delivery of complex care via telemedicine across communities.
WITH SPECIALIZED RESOURCES FOR EACH OF YOUR RESEARCH NEEDS
Syreon provides the specialized research resources required for each particular research program from biomarkers or early phase PK / PD Phase 1/2a studies to at-home telemonitoring of biological functions and monitoring of disease activity or patient preferences rapid and simple ePRO applications. Our computational medicine and modeling teams provide sophisticated data streams for health and economic analysis and AI strategies for real-world evaluation.
Content, communications and
Content expertise is vital for safe and effective development and delivery of powerful medicines. So global experts guide all our teams to ensure world-class performance for our programs.
Real-time communication and data exchange is critical for speed and performance. Our Quality-by-Design digital research network strategies are built into every aspect of operations for success!
From CDISC precision to the application of artificial intelligence for big data analysis. We combine cutting-edge computational methods expertly selected for each of our many global priorities!
An elite portfolio of partners from
global pharma to emerging biotech
With exceptional repeat business over 25 years.
Selecting the top Key Opinion Leaders is vital for any study. Through our extensive scientific contacts we draw global leaders in each disease who can work together to guide our studies and ensure world-class performance.
Quality is the key requirement for any program, without which all effort, investment and opportunities are jeopardized. Our Quality-by-Design strategies are built into every aspect of our operations to ensure success.
Accuracy and speed are critical to meet critical goals, to enable forward planning, and to control financial costs. We pay meticulous attention to ensure these are complementary, not competing, priorities!
What our clients say about us
Innovations and cautions
in the news
THE ROLE OF ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE
Bertalan Mesko offers a penetrating insight into the applications of Artificial Intelligence from molecular sciences to healthcare delivery.
Taylor Francis Online
HEALTH ECONOMICS AND PRICING
MISSING FROM THE PBM HEARINGS: VALUE-BASED DRUG REIMBURSEMENT
Committees in the US Senate and House of Representatives examined the complex practices of pharmaceutical benefit managers.
HEALTHCARE DELIVERY AND RWE
CANADA HEALTH INFOWAY: BRINGING CARE CLOSER TO HOME FOR CANADIANS
A description of Canada's approach to telehealth across provinces and regions, to meet growing needs while reducing time and costs.
Canada Health Infoway